Table 1 Comparison of clinical features between breast tumors associated or not with L3MBTL4 loss (determined by aCGH)

52 (22-84)

51 (24-82)

0.69

0.57

Ductal

152 (78%)

48 (79%)

Lobular

15 (8%)

5 (8%)

Medularry

12 (6%)

2 (3%)

Mixt

8 (4%)

3 (5%)

Other

7(4%)

3 (5%)

0.11

1.76

IBC

33 (15%)

18 (23%)

(0.87-3.5)

Non IBC

191 (85%)

59 (77%)

0.052

pT1

45 (25%)

8 (14%)

pT2

95 (52%)

28 (48%)

pT3

42 (23%)

22 (38%)

1.02E-02

0.46

Negative

96 (48%)

20 (30%)

(0.24-0.85)

Positive

103 (52%)

47 (70%)

1.15E-02

1

38 (19%)

3 (5%)

2

63 (31%)

25 (38%)

3

100 (50%)

38 (58%)

0.11

0.6

Negative

84 (40%)

19 (29%)

(0.31-1.13)

Positive

125 (60%)

47 (71%)

0.32

0.74

Negative

96 (48%)

26 (41%)

(0.4-1.36)

Positive

104 (52%)

38 (59%)

0.39

1.38

Negative

87 (59%)

30 (67%)

(0.65-3)

Positive

60 (41%)

15 (33%)

0.23

0.64

Negative

53 (32%)

12 (23%)

(0.28-1.36)

Positive

112 (68%)

40 (77%)

1

1.03

Negative

145 (85%)

48 (86%)

(0.42-2.83)

Positive

25 (15%)

8 (14%)

8.04E-04

Basal

63 (33%)

17 (23%)

ERBB2

22 (12%)

9 (12%)

Luminal A

52 (27%)

18 (25%)

Luminal B

29 (15%)

27 (37%)

Normal-like

25 (13%)

2 (3%)

0.32

0.62

no

135 (88%)

37 (82%)

(0.23-1.78)

yes

18 (12%)

8 (18%)

0.38

0.73

no

139 (77%)

41 (71%)

(0.36-1.52)

yes

42 (23%)

17 (29%)

90%

81%

0.254

78%

73%

0.271